Allocetra

• Initial data from Enlivex's Phase I/II trial shows Allocetra treatment resulted in 64% average pain reduction in patients with severe knee osteoarthritis who were candidates for knee replacement surgery. • One-third of treated patients experienced complete pain resolution, with pain scores dropping from an average of 9 to 0, demonstrating significant therapeutic potential. • The treatment demonstrated a favorable safety profile in this high-need patient population, marking a potential breakthrough for end-stage osteoarthritis management.

• Enlivex Therapeutics has dosed the first patient in a Phase I clinical trial evaluating Allocetra™ for psoriatic arthritis, with no initial safety concerns. • The trial aims to enroll six patients unresponsive to conventional treatments, assessing safety and changes in pain and disease activity over 12 months. • Allocetra™, an off-the-shelf cell therapy, seeks to reprogram macrophages to their homeostatic state, potentially offering a novel approach for inflammatory conditions. • The psoriatic arthritis treatment market is projected to reach $20.5 billion by 2032, highlighting the need for more effective and safer therapies.

Enlivex Therapeutics has dosed the first 10 patients in the Phase II stage of its Allocetra™ trial for moderate to severe knee osteoarthritis.

Enlivex Therapeutics reports positive interim efficacy data from its Phase I/II trial of Allocetra in patients with moderate to severe knee osteoarthritis.

Enlivex Therapeutics has been authorized by the Danish Medicines Agency to advance Allocetra into Phase II trials for moderate to severe knee osteoarthritis.